To explore the mechanism underlying the antitumor effect of the combination of Gel@Cmab/PCZ and OXA, we performed immunohistochemical (IHC) staining of tumor sections from different treatment groups, focusing on the proliferation marker Ki‐67, apoptosis marker CC3, and markers of the EGFR downstream pathways, p‐Erk1/2 and p‐Akt. Here, MAPK3 is linked to neoplasm.